within Pharmacolibrary.Drugs.ATC.A;

model A11HA07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A11HA07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Inositol is a carbocyclic sugar, classified as a vitamin-like compound, and is involved in cellular signaling as a component of phospholipids in cell membranes. It is used as a dietary supplement and has been investigated for use in various conditions including polycystic ovary syndrome (PCOS), psychiatric disorders, and as a supportive agent in metabolic syndrome. Inositol is not classified as an essential nutrient or a registered pharmaceutical, but is widely available as an over-the-counter supplement.</p><h4>Pharmacokinetics</h4><p>Estimated PK parameters for healthy adults after oral administration as direct clinical PK data are limited. No published peer-reviewed pharmacokinetic studies in humans providing comprehensive compartmental parameters could be identified.</p><h4>References</h4><ol><li><p>Croze, ML, &amp; Soulage, CO (2013). Potential role and therapeutic interests of myo-inositol in metabolic diseases. <i>Biochimie</i> 95(10) 1811–1827. DOI:<a href=\"https://doi.org/10.1016/j.biochi.2013.05.011\">10.1016/j.biochi.2013.05.011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23764390/\">https://pubmed.ncbi.nlm.nih.gov/23764390</a></p></li><li><p>Jasiecka, A, et al., &amp; Jaroszewski, JJ (2014). Pharmacological characteristics of metamizole. <i>Polish journal of veterinary sciences</i> 17(1) 207–214. DOI:<a href=\"https://doi.org/10.2478/pjvs-2014-0030\">10.2478/pjvs-2014-0030</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24724493/\">https://pubmed.ncbi.nlm.nih.gov/24724493</a></p></li><li><p>Antonowski, T, et al., &amp; Wojtkiewicz, J (2022). Pharmacokinetics of . <i>International journal of molecular sciences</i> 23(19) –. DOI:<a href=\"https://doi.org/10.3390/ijms231911246\">10.3390/ijms231911246</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36232547/\">https://pubmed.ncbi.nlm.nih.gov/36232547</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A11HA07;
